hat
Dwòg la reprim pwodiksyon an nan molekil enflamatwa tankou CCL2, MMP-9, ak TNF-α. Depi tisi domaj ak enflamasyon kwonik yo se faktè onkojèn, syantis yo ap etidye kandida yo nan antiksè kansè SR9009 nan oncogene-indwi senescence.
eng
The drug suppresses the production of inflammatory molecules such as CCL2, MMP-9, and TNF-α. Since tissue damage and chronic inflammation are oncogenic factors, scientists are studying the prospects of SR9009 cancer antagonist in oncogene-induced senescence.